Overthe years, pharmacological studies demonstrated the complex GPR120pharmacology and, at the same time, promoted the opportunity to targetit in metabolic disorders, including T2DM (Figure 2).106 The searchfor synthetic GPR120 agonists started from GPR40 ligands, given thesimilar amino acidic sequence of the two receptors. Here, FFAR4 is linked to metabolic disease.